Valion Bio, Inc. Increase (Decrease) in Accounts Payable
Valion Bio, Inc. (VBIO) reported Increase (Decrease) in Accounts Payable of $375.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-14
- Valion Bio, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $10.00K.
- Valion Bio, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $365.00K, a 16.61% increase year-over-year.
- Valion Bio, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$201.00K.
- Valion Bio, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $231.00K.
- Valion Bio, Inc. increase (decrease) in accounts payable for fiscal 2025 was $139.00K.
- Valion Bio, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$588.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $375.00K 10-Q · filed 2026-08-14 | $174.00K derived: sum of 3 quarters · filed 2026-08-14 | $405.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $365.00K 10-Q · filed 2026-05-14 | $164.00K derived: sum of 2 quarters · filed 2026-05-14 | $395.00K derived: sum of 3 quarters · filed 2026-05-14 | $191.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$201.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $30.00K derived: sum of 2 quarters · filed 2026-03-30 | -$174.00K derived: sum of 3 quarters · filed 2026-08-14 | $139.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $231.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $27.00K derived: sum of 2 quarters · filed 2026-08-14 | $340.00K 10-Q · filed 2025-11-14 | $132.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$204.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $109.00K 10-Q · filed 2026-08-14 | -$99.00K derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-03-31 | $313.00K 10-Q · filed 2026-05-14 | $105.00K derived: sum of 2 quarters · filed 2026-05-14 | ||
| 2024-12-31 | -$208.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$588.00K 10-K · filed 2026-03-30 | ||
| 2024-09-30 | -$380.00K 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |